


REMARKS

Upon entry of this Preliminary Amendment, claims 1 to 16 are pending. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Entry of this amendment into the record is requested.

Respectfully submitted,



James M. Kanagy
Agent for Applicants
Registration No. 29,550


GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5014
Facsimile: (610) 270-5090
n:\lkm\p30000\p32371-c1\preliminary amendment.doc

ABSTRACT OF THE DISCLOSURE

Please replace the current Abstract with the following one:

Abstract

Piperazine derivatives of formula (1),



processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of CNS and other disorders are disclosed herein.